fluconazole has been researched along with Communicable Diseases in 6 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Communicable Diseases: An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neuromeningeal cryptococcosis and pulmonary tuberculosis are respectively serious mycotic and bacterial infections occurring in a subject regardless of its HIV serological status." | 1.72 | [Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali]. ( Alle Akakpo, AE; Cissoko, Y; Dao, S; Konaté, I; Loua, OO; Ouedraogo, D; Soumaré, M, 2022) |
| "Antifungals used for treating candidemia were (no IDC/IDC): azoles (74%/42%); echinocandins (0%/46%); liposomal and lipidic complex amphotericin B (0%/12%)." | 1.48 | Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, University hospital. ( Barnini, S; Bertolino, G; Carmignani, C; Dal Canto, L; Desideri, I; Menichetti, F; Ripoli, A; Rosselli Del Turco, E; Sbrana, F; Sozio, E; Tagliaferri, E; Tascini, C, 2018) |
| " However, important issues for improvement could be identified, such as increasing the dosage and duration of treatment in cases of serious infections, and withholding treatment from patients with colonization rather than infection." | 1.31 | Use of fluconazole in daily practice: still room for improvement. ( Hekster, YA; Kullberg, BJ; Meis, JF; Natsch, S; Steeghs, MH; van der Meer, JW, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Loua, OO | 1 |
| Alle Akakpo, AE | 1 |
| Ouedraogo, D | 1 |
| Cissoko, Y | 1 |
| Soumaré, M | 1 |
| Konaté, I | 1 |
| Dao, S | 1 |
| Menichetti, F | 1 |
| Bertolino, G | 1 |
| Sozio, E | 1 |
| Carmignani, C | 1 |
| Rosselli Del Turco, E | 1 |
| Tagliaferri, E | 1 |
| Sbrana, F | 1 |
| Ripoli, A | 1 |
| Barnini, S | 1 |
| Desideri, I | 1 |
| Dal Canto, L | 1 |
| Tascini, C | 1 |
| Cooper, LG | 1 |
| Heydemann, J | 1 |
| Misenhimer, G | 1 |
| Antony, S | 1 |
| Zingg, W | 1 |
| Posfay-Barbe, KM | 1 |
| Pittet, D | 1 |
| Natsch, S | 1 |
| Steeghs, MH | 1 |
| Hekster, YA | 1 |
| Meis, JF | 1 |
| van der Meer, JW | 1 |
| Kullberg, BJ | 1 |
| Lucey, DR | 1 |
| Lucey, CR | 1 |
1 review available for fluconazole and Communicable Diseases
| Article | Year |
|---|---|
Healthcare-associated infections in neonates.
Topics: Anti-Bacterial Agents; Antifungal Agents; Communicable Diseases; Cross Infection; Disease Outbreaks; | 2008 |
5 other studies available for fluconazole and Communicable Diseases
| Article | Year |
|---|---|
[Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali].
Topics: Acetaminophen; Adolescent; AIDS-Related Opportunistic Infections; Communicable Diseases; Cryptococco | 2022 |
Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, University hospital.
Topics: Aged; Antifungal Agents; Antimicrobial Stewardship; Candida; Candidemia; Communicable Diseases; Fema | 2018 |
Use of Intra-Articular Amphotericin B in the Treatment of Candida parasilosis and albicans in Prosthetic Joint Infections (PJI): A Novel Approach to this Difficult Problem.
Topics: Aged; Amphotericin B; Antifungal Agents; Arthroplasty, Replacement, Knee; Candida; Candidiasis; Comm | 2017 |
Use of fluconazole in daily practice: still room for improvement.
Topics: Adult; Antifungal Agents; Communicable Diseases; Drug Prescriptions; Drug Utilization Review; Flucon | 2001 |
Infectious disease emergencies in persons with HIV/AIDS: an update.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Clindamycin; Communicable Diseases; Fluconazole; | 1990 |